With the increasing prevalence of obesity and metabolic deterioration, nonalcoholic fatty liver disease (NAFLD) has emerged as the leading cause of liver diseases worldwide [1]. The disease spectrum of NAFLD can transition from simple hepatic steatosis to nonalcoholic steatohepatitis (NASH), cirrhosis, or liver cancer [2]. A meta-analysis estimated the global prevalence of NAFLD close to approximately 25.24%, with an increasing trend [3]. Another meta-analysis suggested that the prevalence of NAFLD in Asia was increasing year by year, with a pooled annual incidence of 50.9 cases per 1000 persons per year and an overall prevalence of 29.62% as of 2019 [4].
